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Sumumary 
The pore-forming hemolysin ofEstkerickia coli (HlyA), an important virulence factor in extraintes~n~i 
E, cob infections, causes thromboxane generation and related vasoconstriction in perfused rabbit 
lungs (Seeger, W., H. Walter, N. Suttorp, M. Muhly, and S. Bhakdi. 1989.J. Clin. Invest. 84:220). 
We investigated the influence  of pulmonary vascular  "priming" with endotoxin on the responsiveness 
of the lung to a low-dose HIyA challenge. Rabbit lungs were perfused with Krebs Henseleit 
buffer containing 0.1-100 ng/ml Salmonella abortus equii lipopolysaccharide (LPS) for 60-180 min. 
This treatment caused protracted release of tumor necrosis factor into the recirculating medium, 
but did not induce significant alterations  of pulmonary hemodynamics and fluid balance. At 
a dose of 1 ng/ml, HIyA elicited only moderate thromboxane release (<200 pg/ml) and pulmonary 
artery pressure increase (~6 mmHg) in control lungs.  Acceleration and potentiation of both 
the metabolic and vasoconstrictor  response occurred in lungs primed with LPS. This priming 
effect displayed dose (threshold •0.1-1  ng/ml LPS) and time dependencies (threshold *60-90 
min LPS incubation). Maximum thromboxane release and pulmonary artery pressure increase 
surpassed the responses to HlyA in nonprimed lungs by more than 15-fold. Cyclooxygenase 
inhibition and thromboxane-receptor antagonism blocked these effects. These data demonstrate 
that LPS priming synergizes with HIyA challenge to provoke vascular abnormalities  that are 
possibly relevant to the pathogenesis  of organ failure in severe local and systemic infections. 
S 
evere bacterial infection and sepsis are inevitably accom- 
panied by the liberation of toxic microbial substances, of 
which LPS (endotoxin) is the most widely known (1). LPS 
may be released from a bacterial focus or circulating bacilli, 
or may be resorbed in enhanced quantities from the gastroin- 
testinal tract under conditions of compromised mucosal bar- 
rier function (2, 3). Adverse effects evoked by LPS include 
micro-circulatory disturbances that lead to organ failure. These 
events appear to result from the activation of inflammatory 
cells and the production of secondary endogenous mediators 
rather than from direct cellular toxicity of LPS (1, 4, 5). In 
addition,  low concentrations of LPS have been found to 
"prime" inflammatory cells in vitro for an enhanced respon- 
siveness to a second inflammatory stimulus,  e.g., lipid and 
peptide chemoattractants (6-15). In perfused lungs, enhanced 
reactivity to  platelet  activating  factor  was  observed  after 
pretreatment of the isolated organ with endotoxin (16). 
In the present study, we investigated whether LPS priming 
might synergize with the action of a proteinaceous,  pore- 
forming exotoxin to cause vascular abnormalities.  We em- 
ployed Escherichia coli hemolysin (HlyA) 1 as a model toxin, 
since the pathogenetic relevance of this agent has been well 
established in animal models (17-19). An analogous role as 
virulence factor in human infections has been inferred from 
the high association of HIyA production with disease, in- 
cluding pyelonephritis and septicemia (18, 20, 21). HlyA exerts 
a particularly potent action on neutrophils, monocytes, and 
endothelial cells, where secondary cellular events such as gener- 
ation of inflammatory mediators may be mediated not only 
by passive calcium flux through toxin pores, but also via trig- 
Portions of a doctoral thesis by H. A. Ghofrani are incorporated in this 
report.  1  Abbreviation  used in this paper: HlyA, hemolysin. 
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related signal transduction pathway (22-27). In human neu- 
trophils, the toxin thus evokes degranulation, production of 
reactive oxygen species, and lipid mediator synthesis (23-25, 
28).  Interest in HlyA has been boosted by the recognition 
that this toxin represents the prototype of a large family of 
structurally and functionally related pore-forming toxins pro- 
duced by other gram-negative bacterias  (29-34). 
To address possible cooperative effects of LPS priming and 
HlyA efficacy, we have employed the model of the buffer- 
perfused rabbit lung.  This provides a means to investigate 
the pathogenesis of inflammatory organ injury in the absence 
of plasma proteins and circulating blood cells.  Infusion of 
viable HlyA-producing E, toll, but not of genetically related 
toxin-negative strains,  was previously found to provoke pul- 
mona-Dr hypertension and pulmonary edema in the per  fused 
lungs (35).  Similar effects were discerned when low doses 
of purified HlyA were applied (36).  Here, we demonstrate 
a remarkable synergism between LPS and HIyA. Preexposure 
of the perfused rabbit lungs to the LPS primed the organs 
for markedly accelerated and enhanced responsiveness to low- 
dose HIyA challenge.  Such synergism between endotoxin and 
a membrane-damaging exotoxin may be widely operative and 
relevant to the pathogenesis of vascular abnormalities in se- 
vere infection  and sepsis. 
Materials  and Methods 
Rea,fents.  Goat anti-human  TNF-ot  with  established cross- 
reactivity with rabbit  TNF-a was graciously provided by J. C. 
Mathison (Scripps Rasearch Institute, La JoUa, CA}, and Salmonella 
abortus equii endotoxin by C. Galanos (Max Planck Institute  of 
Immunology, Freiburg, Germany). D,t-Lysin-mono-acetylsalicyhte/ 
glycine (9:1; ASA) was obtained from Bayer AG (Leverkusen, Ger- 
many), BM 13.505 from Boehringer AG (Mannheim, Germany), 
and MTT from Sigma (Munich, Germany). Rabbit anti-TxBz was 
from Paesel AG (Frankfurt,  Germany), and recombinant  murine 
TNF-~  from  Genzyme  (Frankfurt,  Germany).  Tritium-labeled 
TxBz was purchased from New England Nuclear (Dreieich, Ger- 
many). A photometric test for the detection of LPS was obtained 
from Kabi Vitrum (Contest endotoxin;  Munich,  Germany).  All 
other biochemicals were obtained from Merck AG (Darmstadt, 
Germany). 
Pre~ration of  HlyA.  HlyA was purified as previously described 
(37). The toxin was recovered in active and monomeric form, and 
the LPS contamination  of the preparation  used was g3 ng//~g 
protein. 
PerfusedRabbit  Lungs.  The model has been previously described 
in detail (38--40). The lungs were perfused with Krebs Henseleit 
buffer through cannulas in the pulmonary artery and the left atrium 
(flow 100 rot/rain;  left atrial pressure 2 mm Hg), being placed in 
a temperature-equilibrated housing chamber at 37~  and freely sus- 
pended from a force transducer. They were ventilated with room 
air supplemented with 4% CO2 (tidal volume 8-14 ml/kg,  fre- 
quency 25-30 breaths/rain;  positive endexpiratory pressure of 1.5 
mmHg). The alternate use of two separate perfusion circuits, each 
containing 250 ml, allowed exchange of perfusion fluid. Perfusion 
pressure, ventilation pressure, and the weight of the isolated organ 
were registered continuously.  Lungs sdected for the study were 
those that (a) had a homogenous white appearance without signs 
of hemostasis or edema formation;  (b) had pulmonary  artery and 
ventilation pressures in the normal range; and (c) were isogravi- 
metric (lung weight gain ~0.3 g/h) during an initial steady state 
period of at least 45 rain. 
Biochemical Measurements.  TxBz was  assayed by RIA as de- 
scribed (19). TNF-~ was determined in a cytolytic cell assay in the 
mouse fibrosarcoma cell line WEHI 164 clone 13 (kindly donated 
by Dr. T. Espevik, University of Trondheim, Trondheim, Norway), 
as previously described (41). The WEHI cells (2  x  104) were in- 
cubated with serial dilutions ofperfusate in microtiter wells (Nunc, 
Rothkilde,  Denmark).  After 18 h, MTT (5 mg/ml in PBS; 100 
#l/well) was added. The reaction was stopped after 4 h by addition 
of 5% formic acid in 2-propanol, and the content of reduced MTT 
was read in a microELISA autoreader (570 nm). The titer of TNF-c~ 
is expressed in U/ml and was chosen as the reciprocal of the dilu- 
tion necessary to cause 50% cytotoxicity.  Recombinant  routine 
TNF-a served as standard in all assays. The sensitivity of WEHI 
164.13 ranged between 0.8 and 0.02 pg protein/cytolytic  unit in 
the different experiments. Rabbit TNF-~v units were expressed as 
picograms of routine recombinant TNF-a protein to compensate 
for the variance in sensitivity. To establish the nature of the cyto- 
lyric activity  as TNF-c~, an  antiserum  directed  against human 
TNF-c~ with established cross-reactivity with rabbit TNF-cr (42) 
was added to the perfusates. It was found that it neutralized all 
cytolytic activity measured with the WEHI cells. Potassium was 
measured according to standard techniques. 
Ext,  eriraentaIProtocol.  After a steady-state period of 40 min, the 
recirculating perfusate was exchanged with fresh buffer medium, 
and time was set at zero. Different quantities  of LPS in 500 ~1 
PBS or the vehicle only were admixed to the buffer fluid and recir- 
culated for 60-180 rain. Thereafter, HlyA, dissolved in 250/~1 sa- 
line, was bolus injected into the pulmonary artery to achieve a final 
buffer concentration  of I ng/ml, and recirculation was continued 
for another  20 rain.  1 ml-perfusate samples for determination  of 
TxB2 and potassium  and 3-ml  samples for TNF measurements 
were taken every hour during the period of LPS or sham priming 
and 2, 5, 10, and 20 min (TxB2, K*) as welt as 20 rain (TNF) 
after application of HlyA. 
Results 
Pressor Responses.  Under baseline conditions, the puLmo- 
nary artery pressure ranged between 5 and 10 mmHg in all 
experiments. Admixture of 0.1 and 1 ng/ml LPS to the buffer 
fluid did not exert any effect on the baseline vascular pressure 
(Fig. 1; Table 1). 10 and 100 ng/ml LPS provQked only minor 
increases  in pressure values that  never exceeded 4 mmHg. 
In nonprimed lungs, bolus injection of 1 ng/ml HlyA caused 
a slight,  protracted rise in pulmonary artery pressure, with 
maximum increases between 5 and 6 mmHg within 20 rain. 
These pressor responses were potentiated in a time- and dose- 
dependent manner by priming with LPS. Taking  I20 rain 
as  standard  priming  time,  pressure increments  up to ~'70 
mmHg were provoked upon subsequent HlyA challenge (Figs. 
1 and 2),  and the vasoconstrictor response occurred much 
more rapidly: more than two thirds of the maximum pres- 
sure rise was complete within  1 rain in lungs primed with 
1 and 10 ng/ml LPS, whereas the maximum pressure eleva- 
tion evoked by HIyA application in nonprimed lungs occurred 
after approximately 20 min. 
Fig. 3 shows the time dependency of the LPS priming pro- 
cess, using 10 ng/ml LPS. No augmentation of the vasocon- 
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Figure 1.  Pulmonary  artery pressure  (PAP)  responses to 1 ng/ml HIyA 
in dependency  on preceding LPS priming. Lungs were perfused with var- 
ious LPS concentrations (oven in ng/ml) for 2 h, followed  by pulmonary 
artery injection of HlyA to achieve  the intended final toxin concentration. 
Mean •  SEM of four independent ~periments each are Oven (SEM bars 
are missing when failing into symbol). (The 122- and 122.5-rain data in 
the group with 100 ng/ml LPS represent only two remaining lung ex- 
periments). 
strictor response was noted upon simultaneous application 
of both LPS and HlyA. A minimal priming period of 60 min 
was required to provoke a moderate amplification of the pressor 
response, and a steep increase in priming efficacy occurred 
in the 60--120  min post-LPS period.  Maximum responses, 
although showing off-leveling of the dose-dependency curve, 
were observed in lungs preexposed to LPS for 180  min. 
Thmmboxane Generation.  Only minor liberation of TxB2 
was noted in control lungs and in lungs undergoing the LPS 
priming procedure up to 3 h (Table 2). Application of I ng/ml 
HlyA alone provoked only moderate thromboxane release 
100 
LPS (ng/ml) 
Figure 2.  Dependency  of the vasoconstrictor  response  evoked  by HlyA- 
on the LPS dose used for priming. Lungs were perfused with various LPS 
concentrations for 2 h, followed  by pulmonary artery injection of HIyA 
(1 ng/ml). Maximum  rises in pulmonary  artery pressure (&/ta PAP) mea- 
sured within 20 min after exotoxin application  are Oven in mean + SEM 
(n  -  4 experiments each). 
(<200 pg/ml). In LPS-primed organs, however, marked liber- 
ation of the prostanoid occurred in response to subsequent 
challenge with the exotoxin, whereby similar strict depen- 
dency on the priming time was noted.  More than 30-fold 
increases  in circulating TxB2 levels were provoked within 20 
min to HlyA challenge in lungs preincubated with 10 ng/ml 
LPS for 2 h. After 3-h priming, a greater than 10-fold in- 
crease in exotoxin-elicited TxB~ levels occurred within only 
2  min. 
TNF Liberation.  Lungs perfused with the buffer alone 
rdcased only very small amounts of  TNF into the recirculating 
fluid. Infusion of LPS resulted in a progressive release of this 
Table  1.  Pulmonary  Artery Pressure (PAP) and Lung Weight Gain (IV) in LPS-exposed Lungs 
PAP (mmHg)  ￿9  w  (g) 
Priming time  LPS-dose  Pre-LPS  Post-LPS  Pre-LPS  Post-LPS 
rain  ng/ml 
120  0  5.5  •  0.4  6.0  •  0 
120  0.1  6.3  •  0.34  6.3  _+  0.6 
120  1  6.0  _  0.57  6.3  •  0.6 
120  10  5.3  _  0.88  8.3  •  1.33 
120  100  6.6  •  0.33  10.0  •  0.57 
0  10  6.0  •  0.58  5.6  •  0.33 
60  10  6.6  •  0.33  7.0  •  0.58 
90  10  6.0  •  0.58  6.6  •  0.89 
120  10  5.3  •  0.88  8.3  •  1.33 
180  10  5.0  •  0.58  9.3  •  0.88 
0.03  •  0.14 
-0.06  _+  0.03 
0.13  •  0.03 
0.13  •  0.09 
0.1  •  0.06 
0.16  •  0.14 
0.06  •  0.08 
0.16  •  0.08 
0.13  •  0.08 
0.06  •  0.12 
0.16  +_ 0.06 
1.0  +  0.06 
0  •  0.11 
0+0.1 
0.06  +  0.12 
-0.03  +  0.06 
0.3  +  0.11 
0.2  +  0.43 
0• 
1.53  •  0.96 
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Figure 3.  Time dependency of LPS priming with respect to vasocon- 
strictor responses provoked by HIyA. Lungs were perfused with 10 ng/ml 
LPS for various time periods, followed by injection of HlyA (final concen- 
tration, 1 ng/ml) into pulmonary artery.  Maximum rises in pulmonary 
artery pressure (delta  PAP) measured within 20 rain after exotoxin applica- 
tion are given in mean  •  SEM (n  =  4 experiments each). 
cytokine (time and dose dependencies are depicted in Fig. 
4).  A  subsequent  20-rain  challenge with  HlyA  had  no 
significant effect on the release of TNF in either primed or 
non-LPS-primed lungs (data not shown). 
Effect of Thromboxane  Inhibition on Pressor  Responses.  Lungs 
were primed with 10 ng/ml LPS for 180 min. Acetylsalicylic 
acid (250/~M) or BM 13.505 (10/~M; 43) was then admixed 
to the buffer fluid 5 rain before HlyA challenge (1 ng/ml; 
n =4 experiments each). Rises in pulmonary artery pressure 
were then found to be restricted  to 8.5  +  2.5 and 6.3  +_ 
1.8 mmHg, respectively, as compared with 64 _+ 12 mmHg 
in the absence of either inhibitor. 
Lung  Edema Formation and Potassium Liberation.  Total 
weight gain of the isolated organs ranged below 2 g over 
the entire LPS priming procedure at all endotoxin doses used 
(Table 1). The dramatic vasoconstrictor responses elicited by 
HIyA in LPS-primed organs resulted in rapid edema forma- 
tion at pulmonary artery pressure levels >30 mmHg. In lungs 
with maximum LPS priming (3-h preincubation with 10 and 
100 ng/ml LPS), the exotoxin-elicited weight gain exceeded 
15 g, and experiments were terminated at this level of edema 
formation. 
LPS priming did not result in any significant liberation 
of potassium into the recirculating buffer medium. Intravas- 
cular application of 1 ng/ml HIyA provoked significant potas- 
Table  2.  Thromboxane B2 Generation in Response to LPS Priming and HIyA  Stimulation 
TxB2-1evels (pg/ml) 
Post-HlyA 
Priming Time  LPS-dose  HlyA-dose  Pre-priming  Post-priming  2'  5  10'  20  ~ 
min  ng  /ml  ng  /ml 
180  0  0  87.0  99.5  103.0  100.3  91.3  79.0 
•  16  +  11  _+  11  •  15  +  6  _+  17 
180  10  0  73.3  116.5  -  -  -  122.3 
_+  15  _+  18  -  -  -  •  16 
180  0  1  72.2  70.2  99.4  123.8  198.0  181.2 
_+  7  •  7  +_  10  •  15  •  67  •  55 
0  10  1  68.0  69.4  69.9  96.0  60.0  70.5 
_+  21  •  12  •  15  •  11  _+  16  •  19 
60  10  1  66.0  64.5  81.0  105.7  120.7  162.7 
•  12  •  8  •  16  •  22  •  28  •  13 
90  10  1  62.0  75.0  136.0  184.0  246.0  823.0 
_  12  •  16  •  27  •  52  •  84  •  351 
120  10  1  58.0  78.0  572.0  605.0  985.0  3133.0 
_+  11  _  14  _+  227  •  102  •  127  +_  903 
180  10  1  74.0  101.0  1191.0  *  *  * 
•  8  +_  17  •  304  *  *  * 
* In lungs with high dose LPS priming for 3 h, HlyA stimulation provoked marked edema formation. These experiments were terminated in advance, 
when total lung weight gain surpassed  15 g. 
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Figure 4.  Liberation  ofTNF  into  the hng perfmate  during  LPS priming. 
Lungs were  perfused  with various  LPS concentrations  for 3 h. TNF con- 
centrations in the recirculating  buffer  fluid  are given (mean +_ SEM; n 
= 4 experiments  each). 
sium release within 20 rain (0.32 _  0.04 mind). These values 
were independent of LPS priming (data  not shown). 
Discussion 
Parenteral application of LPS reproduces pathophysiologic 
sequelae of sepsis and ARDS in many animal models (44). 
The endotoxin responsiveness of the pulmonary vasculature 
in terms of vasoconstriction and vascular leakage is, how- 
ever, species dependent. In the present investigation, no or 
only very minor changes in pulmonary artery pressure and 
lung fluid balance were observed within 3-h exposure of rabbit 
lungs to LPS at concentrations of 0.01-100 ng/ml. This low 
responsiveness  is in accord with data obtained in previous 
studies in buffer-perfused goat (45) and rat lungs (46). It may 
be due to several factors,  including the absence of plasma- 
borne endotoxin binders such as the LPS-binding protein LBP 
(3, 47),  and the lack of endotoxin-sensitive humoral medi- 
ator systems such as the complement cascade. Nevertheless, 
LPS did provoke significant cytokine generation. Kinetics of 
TNF appearance (<120 min) and maximum perfusate con- 
centrations of this cytokine (range up to 500 pg/ml; i.e., 5,000 
O/ml) corresponded roughly to data reported for intact rabbits 
with intravascular endotoxin application (peak TNF concen- 
trations ",,2,500  U/ml plasma within 45-100 rain;  [42]). 
Lung macrophages are a likely source for TNF (48).  It is 
noteworthy that TNF alone provoked no severe vascular ab- 
normalities and organ injury in our experiments. 
When given as sole stimulus, HlyA applied at the very 
low dose of 1 ng/ml provoked only marginal TxB2 release 
and a corresponding moderate increase in pulmonary artery 
pressure (36). However, dramatically altered responses were 
observed in lungs primed with LPS, where amplification and 
acceleration of prostanoid release and pulmonary artery pres- 
sure elevation were registered. The potent vasoconstrictor agent 
thromboxane apparently represented the predominant medi- 
ator of the pressor response. Finally this was largely suppressed 
by cyclooxygenase inhibition and Tx-receptor antagonism. 
The cellular source of thromboxane in our model is not es- 
tablished, however, lung macrophages represent likely candi- 
dates. Preincubation of macrophages with LPS in vitro primes 
these cells for accelerated  and erlhanced arachidonate metabolite 
release in response to subsequent stimulation with opsonized 
zymosan and the calcium-ionophore A23187,  with a half- 
maximal priming time of '~20 min, and a maximal effect 
after 50-60 min (6,  11, 49).  These features correspond ap- 
proximately to the characteristics  of priming time (obvious 
effects after ,x,60 rain) and efficacy (acceleration and enhance- 
ment of response) in the present study. Further to this, in- 
travascularly  sequestered  neutrophils, residing in the capri- 
lary bed despite extensive bultrer-perfusion  of the isohted organs 
(50), may also be targets for synergism between LPS and FIIyA. 
These calls are known to be responsive to both HlyA stimu- 
lation (24, 25) and LPS priming (8-10, 15), and neutrophil- 
derived mediators such as oxygen radicals are potent inductors 
of lung thromboxane generation (43,  51, 52). 
The precise cellular mechanisms of LPS priming are un- 
known, and many possibilities are under discussion (15, 53, 
54). In addition, secondary induction of TNF might add to 
the priming efficacy  of LPS, as suggested from in vitro studies 
(15, 53, 55). These unresolved questions notwithstanding, 
it is important to realize that LPS priming can precipitate 
rapid and total collapse of the lung vascular homeostasis upon 
challenge with a common membrane-damaging toxin. Pore 
formers are produced by many other pathogenic microor- 
ganisms (31, 32, 56, 57), and their synergism with LPS or 
other priming agents could be relevant to the pathogenesis 
and manifestation of organ lesions during severe infections. 
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